Epic Bio

Edit info

Founded: 2018

Location: South SF, CA

Employee range: 11 - 50

Clinical stage: Clin0

Therapy area: Facioscapulohumeral muscular dystrophy

Drug types: GEN, MUS, CVV, OPH

Lead product: EPI-321

Funding: $55M A Jul 2022

epic-bio.com

linkedin.com

job board

Drug notes:

EPI-221 RD heterozygous familial hypercholesterolemia; EPI-241 RD alpha-1 antitrypsin deficiency; EPI-141 RD retinitis pigmentosa 4; EPI-111 RD retinitis pigmentosa 11

About:

Epic Bio is developing ultra-compact therapies to modulate gene expression and treat complex disease. Epigenetics play a key role in the regulation of which genes are expressed within a cell. By leveraging the epigenome, Epic has built their “mix and match” Gene Expression Modulation System (GEMS) platform that can combine epigenomic modulators to create therapies customized for specific disease indications. Part of their toolbox includes CasMINI, the smallest and most deliverable dCas protein to work in human cells. This offers Epic even greater potential for in vivo delivery and multigene disease treatment.